Decoy Therapeutics (NASDAQ:DCOY) Trading Up 3.9% – Still a Buy?

Decoy Therapeutics (NASDAQ:DCOY) shares were up 3.9% during mid-day trading on Monday . The company traded as high as $6.70 and last traded at $6.07. Approximately 11,509 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 31,158 shares. The stock had previously closed at $5.84.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on DCOY shares. LADENBURG THALM/SH SH started coverage on Decoy Therapeutics in a report on Friday, January 23rd. They issued a “buy” rating and a $30.00 target price on the stock. Wall Street Zen raised Decoy Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Weiss Ratings started coverage on Decoy Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Decoy Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Trading Up 1.7%

The stock has a market capitalization of $3.35 million, a P/E ratio of -0.02 and a beta of 0.37. The firm has a fifty day moving average of $7.64.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $43.10 earnings per share for the quarter.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.